KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Paolo A Ascierto, Craig B Davis, Khyati Shah, Phineas Hamilton, Alessandra di Pietro, Keith Flaherty

Clin Cancer Res 32(7) 1266-1276

PMID41537702
PMCIDPMC13040209
DOI10.1158/1078-0432.CCR-25-3262
发表日期2026-01-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Treatment with encorafenib ± binimetinib is associated with improved survival versus vemurafenib in patients with BRAF V600E/K-mutant advanced melanoma. We retrospectively analyzed genomic and transcriptomic data from the phase III COLUMBUS trial to identify molecular correlates of benefit with encorafenib ± binimetinib. EXPERIMENTAL DESIGN: In COLUMBUS, patients with BRAF V600E/K-mutant locally advanced, unresectable, or metastatic melanoma (n = 921) were randomized to receive encorafenib plus binimetinib, encorafenib, or vemurafenib. We used whole-exome sequencing (n = 666), whole-transcriptome sequencing (RNA sequencing; n = 514), and assessment of circulating tumor DNA (ctDNA) at baseline (n = 336) and on treatment (cycle 2 day 1, n = 184) to evaluate biomarker associations with progression-free and overall survival. RESULTS: Survival benefits with encorafenib plus binimetinib versus vemurafenib were greatest in patients with higher tumor mutational burden (TMB) and those with evidence of tumor immune infiltration (i.e., higher cytolytic score, PD-L1 expression, or IFNγ gene signature scores). Clustering of gene expression profiles identified three tumor subgroups, including an "immune" subgroup associated with improved survival. Detection of BRAF V600 alterations in baseline ctDNA was associated with shorter survival; clearance of BRAF V600 alterations at cycle 2 day 1 was associated with improved survival across arms. CONCLUSIONS: The greatest benefits of encorafenib plus binimetinib were observed in patients with evidence of high TMB and/or tumor-immune infiltration, suggesting potential immune contributions to efficacy, which were not observed with vemurafenib. BRAF V600 detectability in ctDNA seems to have utility as a marker of prognosis and response in this population.

KM 提取结果

4 个 Figure · 13 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 1

Figure 1. PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by ( A and B ) TMB and ( C and D ) cytolytic score. E, Volcano plots of univariable gene expression associations with OS in each arm based on z -scored gene expression values. F, Gene-set enrichment analysis of gene expression associations against hallmark gene signatures; signatures with greatest average NES across arms shown. Bini, binimetinib; BM, biomarker; CYT, cytotoxic score; Enco, encorafenib; NES, normalized enrichment scores; Vemu, vemurafenib.

A

PFS

Figure 1 · Panel A

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线交叉次数异常,需检查跨图跳线或误跟踪曲线交叉次数异常,需检查跨图跳线或误跟踪
查看结果
B

OS

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 6 条 已提取 5 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线交叉次数异常,需检查跨图跳线或误跟踪曲线缺失:预期 6 条,实际恢复 5 条
查看结果
C

PFS

Figure 1 · Panel C

quality_warning 待 EXE 对齐 预期 6 条 已提取 4 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 4 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme jump
查看结果
D

OS

Figure 1 · Panel D

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 4:extreme jump曲线 4:extreme upward reversal曲线 5:short span曲线 6:short span
查看结果
KM Figure4 个面板

Figure 2

Figure 2. PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by ( A and B ) ERBB2 expression level and ( C and D ) PI3K pathway mutation status. Bini, binimetinib; BM, biomarker; Enco, encorafenib; Vemu, vemurafenib.

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 6:short span
查看结果
B

OS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
C

PFS

Figure 2 · Panel C

quality_warning 待 EXE 对齐 预期 6 条 已提取 5 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 5 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

OS

Figure 2 · Panel D

quality_warning 待 EXE 对齐 预期 6 条 已提取 3 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 3

Figure 3. Characterization of tumor samples to identify candidate molecular subtypes by K-means clustering and distribution of subtypes by biopsy site. A, Heatmap showing K-means cluster and the expression of key marker genes ( AXL and MITF ) and cell type scores generated by xCell. B, Distribution of K-means subgroups across biopsy sites. C, OS by K-means subgroup and treatment arm. Bini, binimetinib; Vemu, vemurafenib.

C

OS

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 9 条 已提取 7 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线交叉次数异常,需检查跨图跳线或误跟踪曲线缺失:预期 9 条,实际恢复 7 条
查看结果
KM Figure4 个面板

Figure 4

Figure 4. PFS and OS by detection of BRAF V600 alterations in ctDNA at ( A and B ) baseline and ( C and D ) on treatment. Only patients with BRAF V600 alteration detections at baseline are shown in C and D . Bini, binimetinib; D, detectable; Enco, encorafenib; ND, nondetectable; Vemu, vemurafenib.

A

PFS

Figure 4 · Panel A

quality_warning 待 EXE 对齐 预期 6 条 已提取 4 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 4 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

OS

Figure 4 · Panel B

quality_warning 待 EXE 对齐 预期 6 条 已提取 5 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 5 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

PFS

Figure 4 · Panel C

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 4 · Panel D

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果